Pasithea Therapeutics
Announces Plans to Open Three New Clinics in the UK by
Mid-2022
-- Each clinic expected to contribute an estimated USD$5
million (£4 million) annually in revenue --
-- New London locations will provide pharmacy services,
ketamine therapy, and other psychiatric treatments, including
repeated transcranial magnetic stimulation ("rTMS") --
Miami Beach, FL / January 24, 2022 -- InvestorsHub NewsWire
-- Pasithea Therapeutics Corp. (Nasdaq: KTTA) ("Pasithea" or the "Company"), a novel
biotechnology company focused on the research and discovery of new
and effective treatments for psychiatric and neurological
disorders, today announced that its wholly owned subsidiary,
Pasithea Clinics, has expanded its treatment offer and is planning
to open three new clinics in London to treat patients suffering
from mental health issues. The Company already has locations in
Marylebone and Knightsbridge.
"With these new clinics, we will broaden our London footprint
and start offering pharmacy services and new treatment options,
bringing important and novel mental health therapies to an
ever-growing number of people. In addition to pharmacy services,
our London clinics will offer other psychiatric treatment
therapies, including repeated transcranial magnetic stimulation in
addition to intravenous ("IV") ketamine" stated Dr. Tiago Reis
Marques, CEO of Pasithea Therapeutics. "With our strong cash
position and our continued expansion in London, we believe we are
well positioned to bring value to our shareholders," concluded Dr.
Marques.
"We are excited to [partner/expand our partnership] with ZEN
Healthcare, who has been providing pioneering IV therapies in
London for six years. By offering more locations, and a greater
number of treatment options, we continue to work toward closing the
treatment gap and getting millions of people the help they need,"
said Dr. Yassine Bendiabdallah, Managing Director of Pasithea
Clinics in the U.K.
The clinics, which will be operated by Pasithea, with
management support from ZEN Healthcare, are expected to open by
mid-2022. Each clinic will contribute an estimated USD$5 million
annually in revenue.
Repeated transcranial magnetic stimulation ("rTMS") is a
therapeutic brain-stimulation technique based on the principle of
electromagnetic induction. First developed in 1985, rTMS has been
studied as a treatment for depression, psychosis, anxiety, and
other mental health conditions, and has shown particular efficacy
with drug-resistant depressive disorders. In 2008, rTMS was
approved for use by the FDA as a treatment for major depression for
patients who do not respond to at least one antidepressant
medication. A typical plan consists of five treatments per week
over the course of four to six weeks.
Ketamine is a U.S. Food and Drug Administration ("FDA")
approved drug introduced to the medical community as an anesthetic
more than 50 years ago. It has recently been repurposed for the
treatment of psychiatric disorders using significantly lower doses
than in anesthesia and is gaining ground as a promising treatment
for mental health disorders. In certain psychiatric conditions,
such as treatment-resistant depression ("TRD") and post-traumatic
stress disorder ("PTSD"), it has shown remarkable efficacy and a
rapid and sustained effect. While the number of treatments
suggested is done on a case-by-case basis, a typical treatment plan
consists of up to six infusions in the interval of two to three
weeks.
About
Pasithea Therapeutics Corp.
Pasithea Therapeutics
Corporation is a U.S. biotechnology company focused on the research
and discovery of new and effective treatments for psychiatric and
neurological disorders. With an experienced team of experts in the
fields of neuroscience and psychopharmacology, Pasithea is
developing new molecular entities for the treatment of psychiatric
and neurological disorders. Pasithea is also focused on addressing
the needs of patients currently suffering with mental illness by
providing access to IV ketamine infusions both in clinics and
in-home settings.
About ZEN Healthcare
ZEN Healthcare is a luxury pharmacy and health clinic in
London with three branches - Baker Street, Knightsbridge and
Holborn. The clinics comprise a multidisciplinary group of Private
GPs, anti-ageing doctors, pharmacists, nutritionists,
dermatologists and psychotherapists, as well as intravenous
infusions specialists. ZEN Healthcare has been running pioneering
IV therapies in London for six years.
Forward
Looking Statements
This press release contains statements that constitute
"forward-looking statements." Forward-looking statements are
subject to numerous conditions, many of which are beyond the
control of the Company. While the Company believes these
forward-looking statements are reasonable, undue reliance should
not be placed on any such forward-looking statements, which are
based on information available to the Company on the date of this
release. These forward-looking statements are based upon current
estimates and assumptions and are subject to various risks and
uncertainties, including, without limitation, those set forth in
the Company's filings with the SEC. Thus, actual results could be
materially different. The Company undertakes no obligation to
update these statements whether as a result of new information,
future events or otherwise, after the date of this release, except
as required by law.
Pasithea Therapeutics Corp. Company
Contact
Dr. Tiago Reis
Marques
Chief Executive
Officer
E:
tiago@pasithea.com
Pasithea Therapeutics Corp. Investor
Relations
Lisa M.
Wilson
In-Site
Communications, Inc.
T:
212-452-2793
E:
lwilson@insitecony.com